Navigation Links
LSUHSC's Fontham makes history
Date:11/20/2008

Elizabeth T. H. (Terry) Fontham, MPH, DrPH, Dean of the LSU Health Sciences Center New Orleans School of Public Health, will become the first non-physician elected national President of the American Cancer Society when she is inducted at a special ceremony during the Society's National Assembly Meeting on November 20, 2008 in New York City. She will also be the first epidemiologist and the third female to serve as president in the organization's 96-year history.

The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives, and diminishing suffering from cancer through research, education, advocacy, and service. With more than two million volunteers nationwide, the American Cancer Society is one of the oldest and largest voluntary health agencies in the United States.

"Dr. Terry Fontham has dedicated a great deal of her life to fighting cancer, and she has made enormous and life-saving contributions," said Dr. Larry Hollier, Chancellor of LSU Health Sciences Center New Orleans. "We are very proud that the American Cancer Society has recognized Dr. Fontham's strong leadership ability, something we have had the privilege to know firsthand for many years."

Dr. Fontham is the first Dean of LSU Health Sciences Center New Orleans School of Public Health and is Professor of Epidemiology as well as Professor of Pathology in the LSUHSC School of Medicine. A graduate of Tulane University School of Public Health and Tropical Medicine, Dr. Fontham has been on the faculty in the LSU Health Sciences Center since 1980 and was Chairman of the Department of Public Health and Preventive Medicine prior to the establishment of the School of Public Health. She is Associate Director of the LSUHSC Stanley S. Scott Cancer Center and is Senior Consultant Epidemiologist to the Louisiana Office of Public Health.

Dr. Fontham's major
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-452-9166
Louisiana State University Health Sciences Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Smart Technology Makes Patient Data Collection Easier, More Efficient
2. WeissComm Partners Makes 10 New Hires as It Wins New Accounts and Grows Existing Business
3. Independence Blue Cross Makes Music for Members Ears
4. A Place for Mom COO Makes Seattles 40 Under 40 List
5. Sesame Street Exhibition Makes Texas Premier at The Health Museum
6. Study makes progress in zoning in on biomarkers for better colon cancer treatment
7. New Online Tool Makes Enrollment in Blue Cross of California Easier
8. 1-800-PACK-RAT Makes a Splash During Annual Walk for Hope
9. Eye on Safety Makes Halloween Less Scary
10. An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal
11. Michigan State Medical Society Foundation Makes A Difference by Assisting Those in Crisis Shelters
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:Don't I know you? University of Toronto research sheds light on memorial retrieval 2Health News:Antidepressants May Change Your Personality 2Health News:Antidepressants May Change Your Personality 3Health News:Antidepressants May Change Your Personality 4Health News:Oncologist at the Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization 2Health News:Oncologist at the Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization 3Health News:Oncologist at the Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization 4Health News:Anthem Blue Cross and Blue Shield in Maine and National Council on Aging Provide Vital Benefits Information to Economically Challenged Older Adults 2
Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 1HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 2Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 1Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 2Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 3Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 4Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 1Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 3Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 4